Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE2
Resiliency in Older Adults Undergoing Bone Marrow Transplant
- Status
- COMPLETED
- Phase
- N/A
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
- Status
- RECRUITING
- Phase
- PHASE1
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
- Status
- COMPLETED
- Phase
- PHASE2
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
- Status
- TERMINATED
- Phase
- PHASE2
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
- Status
- SUSPENDED
- Phase
- PHASE1
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
- Status
- WITHDRAWN
- Phase
- PHASE1
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Early Palliative Care for Patients With Haematological Malignancies
- Status
- UNKNOWN
- Phase
- PHASE3